The Atlanta Electricals IPO is open for public subscription today, September 22, 2025. The bidding is scheduled to conclude on 24 September 2025. The company has raised ₹205 crore from anchor investors ahead of the IPO.
The Atlanta Electricals IPO is a book-building issue of ₹687.34 crore, consisting of a fresh issue of ₹400 crore and an offer for sale (OFS) of ₹287.34 crore worth of shares. The price band is set between ₹718 and ₹754 per share. The basis of allotment will be finalised by September 25, 2025, and the tentative listing date on BSE and NSE is September 29, 2025.
Click here to check out recently closed IPOs.
22 September 2025 11:12:00]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers (QIBs) |
0.00 |
Non-Institutional Investors |
0.17 |
Retail Individual Investors (RIIs) |
0.25 |
Employees |
0.14 |
Total |
0.16 |
The net proceeds from the fresh will be used towards:
As of 22 September 2025, Atlanta Electricals' IPO GMP stood at ₹140. The expected listing price is ₹894, i.e., an 18.57% gain per share over the upper price band.
Source: Business Standard Report dated 22 September 2025
Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market.
Atlanta Electricals is one of the leading manufacturers of power, auto and inverter-duty transformers. The company is also positioned as one of the limited number of domestic manufacturers capable of producing transformers with capacities up to 200 Mega Volt-Amps (MVA) and voltage ratings up to 220 kilovolts (kV).
Explore other Upcoming IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.